GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Cyclically Adjusted PB Ratio

Astellas Pharma (STU:YPH) Cyclically Adjusted PB Ratio : 2.06 (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Astellas Pharma Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Astellas Pharma's current share price is €9.326. Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €4.53. Astellas Pharma's Cyclically Adjusted PB Ratio for today is 2.06.

The historical rank and industry rank for Astellas Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:YPH' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.97   Med: 2.9   Max: 3.62
Current: 2.06

During the past years, Astellas Pharma's highest Cyclically Adjusted PB Ratio was 3.62. The lowest was 1.97. And the median was 2.90.

STU:YPH's Cyclically Adjusted PB Ratio is ranked worse than
52.73% of 732 companies
in the Drug Manufacturers industry
Industry Median: 1.885 vs STU:YPH: 2.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astellas Pharma's adjusted book value per share data for the three months ended in Mar. 2024 was €5.466. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.53 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Astellas Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted PB Ratio Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.85 2.79 2.95 2.67 2.18

Astellas Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.67 2.99 2.83 2.27 2.18

Competitive Comparison of Astellas Pharma's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PB Ratio falls into.



Astellas Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Astellas Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=9.326/4.53
=2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Astellas Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.466/107.2000*107.2000
=5.466

Current CPI (Mar. 2024) = 107.2000.

Astellas Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.020 98.000 4.397
201409 4.241 98.500 4.616
201412 4.234 97.900 4.636
201503 4.612 97.900 5.050
201506 4.457 98.400 4.856
201509 4.553 98.500 4.955
201512 4.631 98.100 5.061
201603 4.712 97.900 5.160
201606 4.889 98.100 5.343
201609 5.223 98.000 5.713
201612 5.219 98.400 5.686
201703 5.100 98.100 5.573
201706 5.348 98.500 5.820
201709 5.039 98.800 5.467
201712 5.070 99.400 5.468
201803 4.905 99.200 5.301
201806 5.059 99.200 5.467
201809 5.102 99.900 5.475
201812 5.267 99.700 5.663
201903 5.313 99.700 5.713
201906 5.423 99.800 5.825
201909 5.799 100.100 6.210
201912 5.820 100.500 6.208
202003 5.834 100.300 6.235
202006 5.807 99.900 6.231
202009 5.756 99.900 6.177
202012 5.835 99.300 6.299
202103 5.781 99.900 6.203
202106 5.625 99.500 6.060
202109 5.903 100.100 6.322
202112 6.152 100.100 6.588
202203 6.120 101.100 6.489
202206 5.949 101.800 6.265
202209 6.364 103.100 6.617
202212 6.014 104.100 6.193
202303 5.864 104.400 6.021
202306 5.736 105.200 5.845
202309 5.782 106.200 5.836
202312 5.340 106.800 5.360
202403 5.466 107.200 5.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Astellas Pharma  (STU:YPH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Astellas Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (STU:YPH) Business Description

Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (STU:YPH) Headlines

No Headlines